Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

About this update from Median Technologies

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/ae95288c521b202282276d16125d16b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YS3VqkbZz1C7GghHxZhP6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ae95288c521b202282276d16125d16b2","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JNPdyQH42RzRCPx8DLwMgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ae95288c521b202282276d16125d16b2","width":1200,"height":446}},"lazy":false},{"type":"text","content":"The collaboration follows FDA 510(k) clearance for eyonis® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus Pixel platform.","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"SOPHIA ANTIPOLIS, France & CHICAGO, February 12, 2026--(BUSINESS WIRE)--Regulatory News:","length":92,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, today announced its non-exclusive distribution agreement with Tempus AI, Inc. (NASDAQ: TEM) a technology company leading the adoption of AI to advance precision medicine.","length":483,"tagName":"p"},{"type":"text","content":"Under the agreement, Tempus AI will distribute eyonis® LCS to U.S. imaging providers through the Tempus Pixel platform and support implementation, customer onboarding, and workflow integration. Tempus Pixel1 is an FDA-cleared, CE-marked AI-enabled solution that offers advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. It aims to aid providers in making informed diagnostic and disease management decisions.","length":486,"tagName":"p"},{"type":"text","content":"Median announced on February 9, 2026, that eyonis® LCS, its AI-based CADe/CADx Software as a Medical Device (SaMD...

More updates from Median Technologies